full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
http://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for January, 2015

28
Jan

After years of setbacks for the antibiotic ceftobiprole, Basilea Pharmaceutica’s antifungal isavuconazole is now on the cusp of winning FDA approval. And Basilea thinks it and partner Astellas Pharma have a potential blockbuster on their hands. …read more Source: Basilea eyes blockbuster sales after antifungal gets FDA panel OK     

28
Jan

Cantargia is moving ahead with plans to list on Nasdaq First North in Stockholm, Sweden. The IPO is intended to give Cantargia the cash to push ahead with development of its lead candidate, an antibody-based cancer therapy that is on the cusp of entering the clinic. …read more Source: Cantargia hits go on Swedish IPO […]

28
Jan

Novartis has admitted that sales of the vitreomacular adhesion drug it licensed from ThromboGenics have failed to live up to expectations. And while various theories have been put forward to explain the drug’s relative lack of commercial success, Novartis thinks part of the issue dates back to clinical trials. …read more Source: Novartis points to […]

28
Jan

FierceBiotech is co-hosting an invitation-only event (there’s no charge) with One Nucleus at the Queen Mary Innovation Centre in London to discuss how the year ahead is shaping up in the British biotech financing scene. …read more Source: Interested in biotech financing in the U.K.?     

28
Jan

With the Cambridge/Boston biotech supercluster forming a kind of global crossroads for drug development, bankers are going the extra mile to get in on the act. Wells Fargo life sciences specialist Katherine Andersen is uprooting herself from Palo Alto, CA, to make the trek to Boston. …read more Source: Wells Fargo dispatches biotech banker to […]

27
Jan

Pfizer, a deal-minded drugmaker sitting on billions in cash, is more interested in acquiring near-market assets than investing in long-term projects, counting on a blockbuster oncology collaboration to keep its early-stage pipeline afloat. …read more Source: Pfizer’s hunting for safe M&A bets, not high-risk pipeline deals     

27
Jan

Three of the world’s largest drugmakers dialed up their R&D budgets in 2014, as Novartis, Pfizer and Bristol-Myers Squibb spent big on costly late-stage programs with hopes of delivering blockbuster new treatments in the coming year. …read more Source: Novartis, Pfizer and Bristol-Myers hit the gas on R&D last year     

27
Jan

Looking for some insights into the way that environment and biology influence the development of multiple sclerosis, Biogen Idec will team up with Google to sift through a mountain of data on the topic, according to a report from Bloomberg. …read more Source: Google, Biogen team up on MS research: report     

27
Jan

President Barack Obama wants to spend $1.2 billion on the fight against antibiotic-resistant bacteria in the coming fiscal year, nearly doubling the nation’s previous efforts. …read more Source: Obama wants to pour $1.2B into antibiotic R&D     

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off